Immunomodulation by 1,25-dihydroxyvitamin D3: Therapeutic implications in hemodialysis and renal transplantation

Clinical Nephrology

Volumn 66, Issue 4, 2006, Pages 275-283

  Mathieu, C ^a   Jafari, M ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b University of California   (United States)

Author keywords

Graft survival; Transplantation; Vitamin D; Vitamin D analogs

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PARICALCITOL; RAPAMYCIN; STEROID; TACROLIMUS; TX 527; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE DENSITY; BONE METABOLISM; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PULSE THERAPY; GRAFT REJECTION; HEMODIALYSIS; HORMONAL REGULATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; IMMUNE STATUS; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; KIDNEY TRANSPLANTATION; NONHUMAN; REVIEW; SECONDARY HYPERPARATHYROIDISM; SYSTEMATIC REVIEW; UREMIA;

EID: 33749627353     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66275     Document Type: Review

References (82)

1. 3. Proc Natl Acad Sci USA. 1981; 78: 4990-4994.
2. Adorini L, Penna G, Giarratana N, Roncari A, Amuchastegui S, Daniel KC, Uskokovic M. Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid Biochem Mol Biol. 2004; 89/90: 437-441.
3. Adorini L, Amuchastegui S, Daniel KC. Prevention of chronic allograft rejection by vitamin D receptor agonists. Immunol Lett. 2005; 100: 34-41.
4. 3: direct inhibition of NFATp /AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 1995; 15: 5789-5799.
5. Amuchastegui S, Daniel KC, Adorini L. Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Transplantation. 2005; 80: 81-87.
6. 3) has salutary effects on renal allograft function (abstract). Transplantation. 2000; 69: S229.
7. Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med. 1981; 305: 440-443.
8. Becker BN, Hullett DA, O'Herrin JK, Malin G, Sollinger HW, DeLuca H. Vitamin D as immunomodulatory therapy for kidney transplantation. Transplantation. 2002; 74: 1204-1206.
9. + T cells to enhance the development of Th2 cells. J Immunol. 2001; 167: 4974-4980.
10. 3. J Neuroimmunol. 1995; 61: 151-160.
11. 3 in vitro and in vivo. J Neuroimmunol. 1997; 79: 138-147.
12. 3 metabolite, dihydroxycholecalciferol. Immunology. 1987; 61: 457-461.
13. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr. 1998a; 128: 68-72.
14. 1 and IL-4. J Immunol. 1998b; 160: 5314-5319.
15. 3, and the immune system. Am J Clin Nutr 2004; 80 (suppl): 1717S-1720S.
16. 3. Crit Rev Eukaryot Gene Expr. 1998; 8: 19-42.
17. 3 analogues. Steroids. 2001; 66: 213-221.
18. 3 analog and cyclosporine. Transplantation. 1998; 65: 1225-1232.
19. S cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol. 2002; 3: 237-243.
20. 3: a transcriptional modulator of the interferon-γ gene. Eur J Immunol. 1998; 28: 3017-3030.
21. 3. Involvement of NF-κB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998; 101: 252-262.
22. 3 restores thymocyte apoptosis sensitivity in non-obese diabetic (NOD) mice through dendritic cells. J Autoimmun. 2005; 24: 281-289.
23. DeLuca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 2001; 15: 2579-2585.
24. Dong X, Lutz W, Schroeder TM, Bachman LA, Westendorf JJ, Kumar R, Griffin MD. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci USA. 2005; 102: 16007-16012.
25. Dusso A, Brown A, Slatopolsky E. Extrarenal production of calcitriol. Semin Nephrol. 1994; 14: 144-155.
26. 3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab. 1997; 82: 2222-2232.
27. Esteban L, Vidal M, Dusso A. 1α-Hydroxylase transactivation by γ-interferon in murine macrophages requires enhanced C/EBPβ expression and activation. J Steroid Biochem Mol Biol. 2004; 89/90: 131-137.
28. S cells and immune tolerance induction: a regulatory renaissance? Nat Immunol. 2002; 3: 215-217.
29. 3 by human dendritic cells. Blood. 2003; 102: 3314-3316.
30. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol. 2004; 173: 2280-2287.
31. Gkonos PJ, London R, Hendler ED. Hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in a patient with end-stage renal disease and active tuberculosis. N Engl J Med. 1984; 311: 1683-1685.
32. 3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol. 2001; 167: 1945-1953.
33. 3 analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes. 2002; 51: 1367-1374.
34. 3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA. 2001; 98: 6800-6805.
35. 3 analogs in kidney transplant recipients. J Steroid Biochem Mol Biol. 2005; 97: 213-218.
36. Haussler MR, Mangelsdorf DJ, Komm BS, Terpening CM, Yamaoka K, Allegretto EA, Baker AR, Shine J, McDonnell DP, Hughes M, Weigel AL, O'Malley BW, Pike JW. Molecular biology of the vitamin D hormone. Recent Prog Horm Res. 1988; 44: 263-305.
37. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand). 2003; 49: 277-300.
38. Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, Kilby MD, Moss PA, Chakraverty R. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol. 2003; 170: 5382-5390.
39. 3. Endocrinology. 1983; 113: 1950-1957.
40. Johnsson C, Tufveson G. MC 1288 - a vitamin D analogue with immunosuppressive effects on heart and small bowel grafts. Transpl Int. 1994; 7: 392-397.
41. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000; 192: 1213-1222.
42. 3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991; 87: 1103-1107.
43. 3 attenuates the expression of experimental murine lupus of MRL/1 mice. Autoimmunity. 1992a; 12: 143-148.
44. 16-cholecalciferol. Transplantation. 1992b; 54: 762-763.
45. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005; 68: 1973-1981.
46. 3. Diabetologia. 1994a; 37: 552-558.
47. 3] and its analogs are dose-reducing agents for cyclosporine in vitro and in vivo. Transplant Proc. 1994b; 26: 3048-3049.
48. 3 as a dose-reducing agent for cyclosporine and FK 506. Transplant Proc. 1994c; 26: 3130.
49. Mathieu C, van Etten E, Gysemans C, Decallonne B, Kato S, Laureys J, Depovere J, Valckx D, Verstuyf A, Bouillon R. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J Bone Miner Res. 2001; 16: 2057-2065.
50. 3 analogs as immunomodulatory agents. Trends Mol Med. 2002; 8: 174-179.
51. 3 as modulators in the immune system. J Steroid Biochem Mol Biol. 2004; 89 /90: 449-452.
52. Mawer EB, Hayes ME, Still PE, Davies M, Lumb GA, Palit J, Holt PJ. Evidence for nonrenal synthesis of 1,25-dihydroxyvitamin D in patients with inflammatory arthritis. J Bone Miner Res. 1991; 6: 733-739.
53. Moe SM, Zekonis M, Harezlak J, Ambrosius WT, Gassensmith CM, Murphy CL, Russell RR, Batiuk TD. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis. 2001; 38: 792-802.
54. Morgan JW, Kouttab N, Ford D, Maizel AL. Vitamin D-mediated gene regulation in phenotypically defined human B cell subpopulations. Endocrinology. 2000; 141: 3225-3234.
55. 3 with an oxygen atom in their side chain. Biochem Int. 1989; 19: 1143-1149.
56. Mudde AH, van den Berg H, Boshuis PG, Breedveld FC, Markusse HM, Kluin PM, Bijvoet OL, Papapoulos SE. Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer. 1987; 59: 1543-1546.
57. Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem. 2001; 8: 1661-1679.
58. + T cells is induced by immunosuppressive drugs and inhibited by Th1- and Th2-inducing cytokines. Immunol Lett. 2003; 85: 135-139.
59. 3 and its potential effects on renal allograft function. Am J Nephrol. 2002; 22: 515-520.
60. Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, Rutgeerts O, Saint-Arnaud R, Bouillon R, Mathieu C. Identification and immune regulation of 25-hydroxyvitamin D-1-α-hydroxylase in murine macrophages. Clin Exp Immunol. 2000a; 120: 139-146.
61. 3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes. 2000b; 49: 1301-1307.
62. Pakkala I, Taskinen E, Pakkala S, Räisänen-Sokolowski A. MC1288, a vitamin D analog, prevents acute graft-versus-host disease in rat bone marrow transplantation. Bone Marrow Transplant. 2001; 27: 863-867.
63. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D. Targeted ablation of the 25-hydroxyvitamin D 1α-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA. 2001; 98: 7498-7503.
64. 3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000; 164: 2405-2411.
65. 3 receptors in human leukocytes. Science. 1983; 221: 1181-1183.
66. Pryke AM, Duggan C, White CP, Posen S, Mason RS. Tumor necrosis factor-alpha induces vitamin D-1-hydroxylase activity in normal human alveolar macrophages. J Cell Physiol. 1990; 142: 652-656.
67. Räisänen-Sokolowski AK, Pakkala IS, Samila SP, Binderup L, Häyry PJ, Pakkala ST. A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation. 1997; 63: 936-941.
68. 3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int. 2002; 61: 288-296.
69. Serreze DV, Leiter EH. Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. J Immunol. 1988; 140: 3801-3807.
70. Sezer S, Uyar M, Arat Z, Özdemir FN, Haberal M. Potential effects of 1,25-dihydroxyvitamin D(3) in renal transplant recipients. Transplant Proc. 2005; 37: 3109-3111.
71. 3-1α-hydroxylase in human monocytes. J Bone Miner Res. 2006; 21: 37-47.
72. 3 1α-hydroxylase and vitamin D synthesis. Science. 1997; 277: 1827-1830.
73. 3 as an immunomodulator in renal transplant recipients: a retrospective cohort study. Transplant Proc. 2003; 35: 2885-2887.
74. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349: 446-456.
75. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16: 1115-1125.
76. 3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing. Eur J Immunol. 2004; 34: 1068-1076.
77. 3 receptor. Implications for allosteric influences on nuclear receptor structure and function by a DNA element. J Biol Chem. 1998; 273: 10338-10348.
78. 3 as dose-reducing agents for classical immunosuppressants. Transplantation. 2000; 69: 1932-1942.
79. 3 as pluripotent immunomodulatorys. J Cell Biochem. 2003; 88: 223-226.
80. 3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun. 2004; 23: 233-239.
81. 3 receptor in the immune system. Arch Biochem Biophys. 2000; 374: 334-338.
82. Verstuyf A, Segaert S, Verlinden L, Bouillon R, Mathieu C. Recent developments in the use of vitamin D analogues. Expt Opin Invest Drugs. 2000; 9: 443-455.